^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Biliary Tract Cancer

    Related cancers:
    1d
    Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Sep 2026 | Trial primary completion date: Mar 2025 --> Sep 2026
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    2d
    From progression to complete remission - a case study of successful pemigatinib treatment in a patient with metastatic FGFR2+ cholangiocarcinoma. (PubMed, Klin Onkol)
    This case demonstrates the significant therapeutic potential of pemigatinib in a patient with metastatic cholangiocarcinoma with FGFR2 fusion, where complete disease remission was achieved after previous progression on standard treatment.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • BICC1 (BicC Family RNA Binding Protein 1)
    |
    FGFR2 fusion • FGFR fusion
    |
    Pemazyre (pemigatinib)
    2d
    A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Koselugo (selumetinib)
    6d
    Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients. (PubMed, J Transl Med)
    Our findings show that candidate immunogenic neoantigen peptides can be identified in CCA and are supported by proof-of-concept functional validation. Together, these results provide a framework for the downstream validation of neoantigen targets and the development of personalized immunotherapy approaches.
    Journal • Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)
    7d
    SIAG-BTC: Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC. (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Yervoy (ipilimumab) • gemcitabine • Tyvyt (sintilimab) • albumin-bound paclitaxel
    8d
    Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies. (PubMed, Curr Pharm Des)
    Advances in molecular profiling and immunotherapy are reshaping the management of cholangiocarcinoma, enabling more personalized treatment strategies. Continued integration of precision oncology into clinical practice and prospective trials will be critical to improving outcomes for cholangiocarcinoma moving forward.
    Journal
    |
    MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • FGFR (Fibroblast Growth Factor Receptor)
    |
    cisplatin • gemcitabine • capecitabine
    8d
    Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, HuiKai Li
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    9d
    SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors (clinicaltrials.gov)
    P2, N=150, Recruiting, Shenyang Sunshine Pharmaceutical Co., LTD.
    New P2 trial
    |
    SSGJ-705
    9d
    Proof-of-principle 4-marker spatial profiling reveals distinct, location-independent immune clusters in biliary tract cancers. (PubMed, Pathol Oncol Res)
    Despite advances with durvalumab plus chemotherapy, prognosis remains poor. However, among patients treated with adjuvant cisplatin/gemcitabine alone, lower CD20/CD8 fractions and higher CD163 abundance at baseline were associated with improved survival. Spatial immune profiling revealed distinct BTC immune architectures at the invasive margin, with different possible impact on survival, thus warranting further characterization and validation in larger cohorts.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • ARID1A (AT-rich interaction domain 1A) • CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    11d
    Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer. (PubMed, Cancer Med)
    We demonstrated the real-world genomic characteristics of BTC patients, which may have promising implications for the development and application of precision medicine in the future. Well-designed prospective studies are mandatory to validate the predictive role of significant genomic alterations observed in our study.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NF1 (Neurofibromin 1) • LRP1B (LDL Receptor Related Protein 1B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • MSH3 (MutS Homolog 3)
    12d
    A Phase I Clinical Study to Evaluate the Efficacy and Safety of GB18 Injection in Patients With Tumor Cachexia (clinicaltrials.gov)
    P1, N=18, Recruiting, Kexing Biopharm Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    GDF15 (Growth differentiation factor 15)
    12d
    IMC001 EpCAM: Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors. (clinicaltrials.gov)
    P1/2, N=30, Enrolling by invitation, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1/2 trial
    |
    IMC001 • danburstotug (IMC-001)